DPP4 and type 2 diabetes mellitus: Wen-Lian Wu et al. developed the new tricyclic scaffold into a very potent and selective series of DPP-4 (Dipeptidyl peptidase IV) inhibitors for the treatment of type 2 diabetes [14].